^
Association details:
| Biomarker: | ASXL1 mutation + ATM mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | venadaparib (NOV 1401) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer.
Published date:
05/25/2023
Excerpt:
Patients with ATMmASXL1m (n = 3) had a 33% overall response rate (1 partial response, 2 stable disease, range of progression-free survival (PFS), 23-113 weeks)...In this exploratory analysis, patients with co-occurring ATMm and ASXL1m showed higher tumor response. This signals potential value from ATM and ASXL1 co-mutation predicting efficacy of Venadaparib in PC...
DOI:
10.1200/JCO.2023.41.16_suppl.e15019
Trial ID:
